Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
about
Potential role of nonstatin cholesterol lowering agentsBinding Modes of Zaragozic Acid A to Human Squalene Synthase and Staphylococcal Dehydrosqualene SynthaseCholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cellsCompound prioritization methods increase rates of chemical probe discovery in model organisms.Exploration of Peptide Inhibitors of Human Squalene Synthase through Molecular Modeling and Phage Display Technique.Aryl hydrocarbon receptor regulates the cholesterol biosynthetic pathway in a dioxin response element-independent mannerRegulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station".Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's diseaseHuman cholesterol metabolism and therapeutic molecules.Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphateBiological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology.Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs.Regulation of dolichol-linked glycosylation.Transcriptome analysis of the Aspergillus nidulans AtmA (ATM, Ataxia-Telangiectasia mutated) null mutant.The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071.A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.Detection of nonsterol isoprenoids by HPLC-MS/MS.Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease.In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells.Ergosterol biosynthesis and drug development for Chagas disease.Genetic engineering and molecular characterization of yeast strain expressing hybrid human-yeast squalene synthase as a tool for anti-cholesterol drug assessment.Construction of carotenoid biosynthetic pathways using squalene synthase.Bi-allelic Mutations in LSS, Encoding Lanosterol Synthase, Cause Autosomal-Recessive Hypotrichosis Simplex
P2860
Q27009231-4EFD4089-0DC5-4E3D-9B84-C532E56F2D36Q27678314-6FAB6DDC-5CCC-43C8-A394-B8C6C5C83B96Q28829206-922787F5-C4AA-4DCC-9524-E34B355E84EBQ34061093-437A1A6E-29F5-4109-98EC-6D95470E1AB7Q35800044-74D4CF2B-69A8-41DA-97EB-E0CC77C9A8CAQ35923118-E48BC888-A619-4D26-9015-D0608DE1A32BQ36071668-ED346D31-6BF1-4163-B34A-68CAF51867DCQ36584677-F259530F-C1F5-465F-9964-8CB60E8FF12EQ37047547-9593833F-2622-46EA-9F48-21EE19A21F5CQ37192724-724797F2-F1DE-4B40-BA9B-017D612AB30EQ37377399-EF29DC4E-22CA-4BB5-A7A6-6180A3B390D9Q37579675-09AECF56-DB38-4C2B-BC2F-D37F2B100C7EQ38020336-28B318C3-B63D-4BB5-BB23-82A84F0EA577Q38298177-6DB23116-0398-402A-97F9-AEC292B88244Q38901012-7E7E1739-2B73-482F-9D69-7562D14DC8D6Q38989942-4ACA62CC-F35F-4A17-A804-95C553D56999Q39374283-0C522E78-0BAD-41A4-8B48-4A5619681935Q39941512-5FD8F175-AD99-444D-A35A-6FF75C4DB043Q41186266-62CEA0CD-929E-4D97-9DAF-7903B5441005Q42111860-6B837C9B-CD2C-428D-8D6C-275398F6E4DBQ42519931-2252F9B5-1C6B-48EA-8907-DA424499688DQ43276756-62CF436C-0B1C-43B1-85CF-F41FFA022299Q51565685-390AF699-01D6-46B9-89ED-2A10A4626D93Q54447479-50D4A04D-FEB2-4298-A2C2-8A11ABECE1B9Q58618780-05E64ECE-2667-45A2-8145-C394A283E389
P2860
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@ast
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@en
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@nl
type
label
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@ast
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@en
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@nl
prefLabel
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@ast
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@en
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@nl
P3181
P1433
P1476
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
@en
P2093
Paul N Durrington
P3181
P356
10.2165/00003495-200767010-00002
P407
P577
2007-01-01T00:00:00Z
P6179
1040641798